title: Clinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in Japan.
abstract: BACKGROUND
  Peramivir is an intravenously administered neuraminidase inhibitor for influenza. The clinical efficacy of peramivir remains unclear because it is used in a limited number of countries. We compared the clinical efficacy of peramivir with that of oseltamivir in influenza patients during the 2012-2013 season.
  
  
  METHODS
  Thirty-two influenza patients who were hospitalized at Teikyo University Hospital, a teaching hospital in Tokyo, Japan, from October 2012 to March 2013 were enrolled. Among them, 23 and 9 were treated with peramivir and oseltamivir, respectively. The end points of this study were the time to defervescence and survival rate.
  
  
  RESULTS
  There were no significant differences in the clinical backgrounds of the two groups. However, patients treated with peramivir tended to have a higher incidence of consciousness disturbance [34.8% (8/23) vs 0.00% (0/9), P = 0.064]. There were no significant differences between the peramivir and oseltamivir groups with respect to the time to defervescence (30.9 ± 18.7 h vs 34.7 ± 18.6 h) or survival rate [95.7% (22/23) vs 100% (9/9), respectively].
  
  
  CONCLUSIONS
  The clinical efficacy of peramivir is non-inferior to that of oseltamivir, although peramivir tended to be used in patients with serious complications. Intravenous administration of peramivir may be useful for patients with serious complications, such as consciousness disturbances.
authors.affiliation: Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Yoshino
authors.forename: Kazunori
authors.initials: K
authors.lastname: Seo
authors.forename: Ichiro
authors.initials: I
authors.lastname: Koga
authors.forename: Takatoshi
authors.initials: T
authors.lastname: Kitazawa
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ota
mesh_terms: D000146:Acids, Carbocyclic; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000627:therapeutic use*; D003517:Cyclopentanes / Q000627:therapeutic use*; D005260:Female; D006146:Guanidines / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D009980:Influenza A virus; D007251:Influenza, Human / Q000175:diagnosis / Q000188:drug therapy*; D007564:Japan; D008297:Male; D008875:Middle Aged; D053139:Oseltamivir / Q000627:therapeutic use*; D012189:Retrospective Studies; D012621:Seasons; D016896:Treatment Outcome
chemical_list: D000146:Acids, Carbocyclic; D000998:Antiviral Agents; D003517:Cyclopentanes; D006146:Guanidines; D053139:Oseltamivir; C414210:peramivir
keywords: clinical efficacy; influenza; oseltamivir; peramivir